CagriSema is a once-weekly injection of semaglutide and cagrilintide. Clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a ...

Microdosing is the off-label use of GLP-1 receptor agonists at doses lower than those approved for the treatment of diabetes or obesity. There are numerous reasons people may explore microdosing, ...

This educational article was made possible with materials and support from Tandem Diabetes Care. Automated insulin delivery (AID) systems have been traditionally used by people with type 1 diabetes ...

Because GLP-1 receptor agonists slow down digestion, they may delay the absorption of oral medications like birth control pills, which could affect ovulation and fertility. As more people begin taking ...

A mix of helpful diabetes technology you can use now and cutting edge advances on the horizon were on display at the 2025 ATTD conference in Amsterdam. Researchers presented a vision of the ...

Many important molecules in the body are peptides. Some peptides, like GLP-1, can be modified into effective medications for a variety of conditions, including diabetes. Recently, health, wellness, ...

Many people with diabetes struggle to manage mealtime blood sugar levels, even with new advances in technology. In a clinical trial of adults with type 1 diabetes, the inhaled insulin Afrezza ...

The American Diabetes Association recently released major diabetes care updates, which include new recommendations on diabetes technology, therapy, and preventative health. The ADA's annual Standards ...

Keeping blood sugars in balance is crucial for people with diabetes. Fenugreek, apple cider vinegar, and supplements like fiber and zinc are all-natural treatments that may help lower glucose levels.

Here are some of the top technology highlights covered at the American Diabetes Association's 2026 scientific conference in New Orleans. Broadening access to diabetes technology and developing new ...

The first successful transplants of insulin-producing cells in people with type 1 diabetes occurred about 25 years ago. In recent years, advances once considered hypothetical, such as creating and ...

The FDA approved Proclaim XR, a new implantable spinal cord stimulation device, as a treatment for pain from diabetes-related nerve damage. In January 2023, Abbott announced that the FDA approved its ...